BE896205A - Nouvelles formulations pharmaceutiques contenant le coenzyme q10 adaptees pour l'administration topique - Google Patents

Nouvelles formulations pharmaceutiques contenant le coenzyme q10 adaptees pour l'administration topique

Info

Publication number
BE896205A
BE896205A BE0/210350A BE210350A BE896205A BE 896205 A BE896205 A BE 896205A BE 0/210350 A BE0/210350 A BE 0/210350A BE 210350 A BE210350 A BE 210350A BE 896205 A BE896205 A BE 896205A
Authority
BE
Belgium
Prior art keywords
pharmaceutical formulations
topical administration
formulations containing
novel pharmaceutical
containing coenzyme
Prior art date
Application number
BE0/210350A
Other languages
English (en)
Original Assignee
Seuref Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11165341&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE896205(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seuref Ag filed Critical Seuref Ag
Publication of BE896205A publication Critical patent/BE896205A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE0/210350A 1982-03-19 1983-03-18 Nouvelles formulations pharmaceutiques contenant le coenzyme q10 adaptees pour l'administration topique BE896205A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT20274/82A IT1157269B (it) 1982-03-19 1982-03-19 Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica

Publications (1)

Publication Number Publication Date
BE896205A true BE896205A (fr) 1983-07-18

Family

ID=11165341

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/210350A BE896205A (fr) 1982-03-19 1983-03-18 Nouvelles formulations pharmaceutiques contenant le coenzyme q10 adaptees pour l'administration topique

Country Status (7)

Country Link
US (1) US4654373A (fr)
JP (1) JPS58222016A (fr)
BE (1) BE896205A (fr)
DE (1) DE3309850A1 (fr)
FR (1) FR2523443B1 (fr)
GB (1) GB2116426B (fr)
IT (1) IT1157269B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2587212A1 (fr) * 1985-04-30 1987-03-20 Seuref Ag Compositions pharmaceutiques vasculoprotectrices contenant un derive d'ubiquinone et au moins un autre compose a activite vasculoprotectrice

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1157269B (it) * 1982-03-19 1987-02-11 Seuref Ag Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica
JPS5913710A (ja) * 1982-07-15 1984-01-24 Shiseido Co Ltd 養毛料
JPS60100517A (ja) * 1983-11-08 1985-06-04 Eisai Co Ltd 放射線潰瘍治療剤および方法
JPS61210028A (ja) * 1985-03-15 1986-09-18 Eisai Co Ltd 褥瘡治療剤
JPS61289029A (ja) * 1985-06-11 1986-12-19 Shiseido Co Ltd 抗色素沈着剤
JPS6339813A (ja) * 1986-08-05 1988-02-20 Eisai Co Ltd 創傷治療剤
US4929437A (en) * 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5378461A (en) * 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US6461593B1 (en) * 1992-02-19 2002-10-08 Biomedical And Clinical Research Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US6255354B1 (en) * 1997-02-12 2001-07-03 Mse Pharmazeutika Gmbh Preparation of a pulmonary surfactant for instillation and oral application
WO1998035658A2 (fr) * 1997-02-12 1998-08-20 Mse Pharmazeutika Gmbh Utilisation de 2,3-dimethoxy-5-methyle-6-decaprenyle-1,4-benzoquinone
US6503483B2 (en) * 1997-06-12 2003-01-07 C.S. Bioscience, Inc. Dental formulation
US6207137B1 (en) 1997-06-12 2001-03-27 C.S. Bioscience, Inc. Dental formulation
US5908613A (en) * 1997-09-08 1999-06-01 Bozzacco; Craig Composition for the treatment and prevention of periodontal disease
DE19806947A1 (de) * 1998-02-19 1999-08-26 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus mindestens einer Substanz gewählt aus der Gruppe, bestehend aus Carnitin und den Acylcarnitinen, und mindestens einem Chinon und oder mindestens einem Hydrochinon sowie Zubereitungen mit einem Gehalt an solchen Wirkstoffkombinationen
US6048886A (en) * 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
US6106286A (en) * 1999-01-22 2000-08-22 Gupta; Subhash Method and device for administering medicine to the periodontium
DE19944137A1 (de) * 1999-09-15 2001-03-22 Beiersdorf Ag O/W-Emulsionen mit einem Gehalt an einem oder mehreren Biochinonen und einem erhöhten Gehalt an Glycerin
ES2310549T3 (es) * 2000-05-09 2009-01-16 Kaneka Corporation Composiciones dermicas que contienen coenzima q como principio activo.
DE10036798A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Mittel zur Behandlung der Haare und der Kopfhaut
US6372198B1 (en) * 2000-09-14 2002-04-16 Joseph M. Abbate Dentifrice for the mineralization and remineralization of teeth
KR100612398B1 (ko) * 2000-11-14 2006-08-16 바이탈 헬스 사이언시즈 피티와이 리미티드 포스페이트 유도체의 착체
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
US6864231B2 (en) * 2001-01-09 2005-03-08 Pharmachem Laboratories, Inc. Glycoprotein matrix compositions and methods related thereto
US6806069B2 (en) * 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
DE10111053A1 (de) * 2001-03-06 2002-09-12 Beiersdorf Ag Wirkstoffkombinationen aus alpha-Liponsäure und Biochinonen
US20030031688A1 (en) * 2001-04-02 2003-02-13 Dipak Ghosh Cosmetic composition with improved skin moisturizing properties
AU2002317053B2 (en) 2001-07-27 2004-08-05 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
DE10139851A1 (de) * 2001-08-14 2003-03-13 Beiersdorf Ag Hautpflegeprodukte mit einer Kombination aus Biotin, Ubichinonen und Cyclodextrinen
DE10146802A1 (de) * 2001-09-22 2003-04-24 Beiersdorf Ag Vitaminhaltige Hautpflegeprodukte
TWI329513B (en) * 2001-10-12 2010-09-01 Kaneka Corp Use of reduced coenzyme q for lessening oxidative stress
BR0215102A (pt) * 2001-12-13 2004-11-03 Vital Health Sciences Pty Ltd Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US7544674B2 (en) * 2002-10-25 2009-06-09 Galderma S.A. Topical skin care composition
BRPI0406484A (pt) * 2003-01-17 2005-12-06 Vital Health Sciences Pty Ltd Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US20070140999A1 (en) * 2003-07-18 2007-06-21 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
EP1696868A1 (fr) * 2003-07-18 2006-09-06 Hill Dermaceuticals, Inc. Composition topique de soins de la peau contenant de l'huile de cacahuetes raffinee
US20060099173A1 (en) * 2003-10-24 2006-05-11 Nancy Puglia Topical skin care composition
ES2410587T3 (es) 2004-01-22 2013-07-02 University Of Miami Formulaciones tópicas de coenzima Q10 y métodos de uso
CA2557354C (fr) 2004-03-03 2013-05-07 Vital Health Sciences Pty Ltd. Formulations alcaloides
DE102004032837A1 (de) 2004-07-02 2006-02-09 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus einem oder mehreren Biochinonen und einem oder mehreren Isoflavonen zur Verbesserung der Hautkonturen
WO2006092024A1 (fr) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Composés ayant des propriétés anticancéreuses
JP2006248940A (ja) * 2005-03-09 2006-09-21 Eikodo Honten:Kk 皮膚若しくは毛髪用化粧料
MX2007015949A (es) * 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
WO2007070981A1 (fr) * 2005-12-23 2007-06-28 Vital Health Sciences Pty Ltd Composés ayant des propriétés modulatrices de la cytokine
US20070237735A1 (en) * 2006-03-31 2007-10-11 Laboratoires Dermo-Cosmetik Inc. Anti-aging composition, kit and method of use
MX337408B (es) 2007-03-22 2016-03-03 Berg Llc Formulaciones topicas que tienen biodisponibilidad aumentada.
WO2009126764A1 (fr) 2008-04-11 2009-10-15 Cytotech Labs, Llc Procédés et utilisation d'induction de l'apoptose dans des cellules cancéreuses
EA023913B1 (ru) * 2009-05-11 2016-07-29 БЕРГ ФАРМА ЭлЭлСи Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
DE102009027024A1 (de) 2009-06-18 2010-12-23 Henkel Ag & Co. Kgaa Antifalten-Kosmetikum mit Antioxidantien
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
KR101907411B1 (ko) * 2010-03-12 2018-10-12 베르그 엘엘씨 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법
JP5806287B2 (ja) 2010-03-30 2015-11-10 フォスファジェニクス リミティド 経皮送達パッチ
DE102010050570A1 (de) * 2010-11-05 2012-05-10 F. Holzer Gmbh Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors
WO2012122586A1 (fr) 2011-03-15 2012-09-20 Phosphagenics Limited Nouvelle composition
CN103608323B (zh) 2011-04-04 2016-08-17 博格有限责任公司 治疗中枢神经系统肿瘤的方法
CN107095863A (zh) 2011-06-17 2017-08-29 博格有限责任公司 可吸入药物组合物
EP2983654B1 (fr) 2013-04-08 2025-11-12 BPGbio, Inc. Traitement du cancer à l'aide de polythérapies par coenzyme q10
WO2015035094A1 (fr) 2013-09-04 2015-03-12 Berg Llc Procédés de traitement du cancer par perfusion continue de coenzyme q10
DE202014003725U1 (de) 2014-05-06 2014-05-14 Beiersdorf Ag Kosmetisches Produkt
DE102014208441A1 (de) 2014-05-06 2015-11-12 Beiersdorf Ag Zubereitungen mit einer äußeren Gelphase und einer inneren partikulären Phase, die stabilisierte oxidations- und/oder UV-empfindliche Wirkstoffe enthält
DE102014208436B4 (de) 2014-05-06 2016-02-25 Beiersdorf Ag Perlenförmige kosmetische Darreichungsformen
DE102014208440B4 (de) 2014-05-06 2018-09-27 Beiersdorf Ag Zubereitungen mit einer äußeren Gelphase und einer inneren partikulären Phase, die stabilisierte oxidations- und/oder UV-empfindliche Wirkstoffe enthält
PL2942045T3 (pl) 2014-05-06 2019-02-28 Beiersdorf Ag Kosmetyczne perłowe postaci preparatu
DE202014003724U1 (de) 2014-05-06 2014-05-14 Beiersdorf Ag Zubereitungen mit einer äußeren Gelphase und einer inneren partikulären Phase, die stabilisierte oxidations-und/oder UV-empfindliche Wirkstoffe enthält
DE102014208438A1 (de) 2014-05-06 2015-11-12 Beiersdorf Ag Perlenförmige kosmetische Darreichungsformen
PL2942046T3 (pl) 2014-05-06 2019-04-30 Beiersdorf Ag Preparaty z zewnętrzną fazą żelową i wewnętrzną fazą cząsteczkową,która zawiera ustabilizowane substancje wrażliwe na utlenianie i/lub promieniowanie uv
DE102014208451A1 (de) 2014-05-06 2015-11-12 Beiersdorf Ag Kosmetisches Produkt
DE102014208450B4 (de) 2014-05-06 2017-04-06 Beiersdorf Ag Kosmetisches Produkt
DE202014003722U1 (de) 2014-05-06 2014-06-05 Beiersdorf Ag Perlenförmige kosmetische Darreichungsformen
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
DE102016225095B4 (de) 2016-12-15 2024-08-29 Henkel Ag & Co. Kgaa "Kosmetische Gesichtspflegeformulierungen zur Stimulierung der körpereigenen Abwehr gegen freie Radikale"
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法
DE102018210184A1 (de) 2018-06-22 2019-12-24 Beiersdorf Ag Kosmetisches Produkt, umfassend kosmetisches oder dermatologisches Produkt, enthaltend sichtbare, in einem transparenten, flüssigen oder gelförmigen Träger suspendierte Perlen, wobei die Perlen einen unangenehmen Eigengeruch entwickelnden kosmetischen oder dermatologischen Wirkstoff verkapseln

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1317865A (en) * 1971-11-15 1973-05-23 Jujo Paper Co Ltd Biologically active composition
JPS5299223A (en) * 1976-02-14 1977-08-19 Eisai Co Ltd Medicines for alopecia areata
JPS5938202B2 (ja) * 1976-03-05 1984-09-14 エーザイ株式会社 難聴治療剤
JPS5489036A (en) * 1977-12-27 1979-07-14 Eisai Co Ltd Remedy and preventive for hypersensitivity to light
JPS5618914A (en) * 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
FR2472384A1 (fr) * 1979-12-27 1981-07-03 Sederma Sa Utilisation en cosmetologie de complexes naturels constitues d'ubiquinones et de phospholipides
JPS58113127A (ja) * 1981-12-28 1983-07-05 Ajinomoto Co Inc ユビデカレノン含有水性液
IT1157269B (it) * 1982-03-19 1987-02-11 Seuref Ag Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2587212A1 (fr) * 1985-04-30 1987-03-20 Seuref Ag Compositions pharmaceutiques vasculoprotectrices contenant un derive d'ubiquinone et au moins un autre compose a activite vasculoprotectrice

Also Published As

Publication number Publication date
GB8307759D0 (en) 1983-04-27
US4654373A (en) 1987-03-31
GB2116426A (en) 1983-09-28
FR2523443B1 (fr) 1986-10-03
DE3309850A1 (de) 1983-09-29
GB2116426B (en) 1985-09-25
JPS58222016A (ja) 1983-12-23
FR2523443A1 (fr) 1983-09-23
IT8220274A0 (it) 1982-03-19
IT1157269B (it) 1987-02-11

Similar Documents

Publication Publication Date Title
FR2523443B1 (fr) Nouvelles formulations pharmaceutiques contenant le coenzyme q10 adaptees pour l'administration topique
BE849632A (fr) Composition pharmaceutique pour l'administration orale
BE845613A (fr) Preparations pharmaceutiques pour l'administration orale renfermant un ester-17beta de nandrolone et nouveaux esters- 17beta de nandrolone
BE896986A (fr) Derives d'indole, procedes pour leur preparation et composition pharmaceutiques les contenant
FR2540726B1 (fr) Compositions pharmaceutiques anti-inflammatoires pour l'usage topique, leur preparation et leurs utilisations
DZ1077A1 (fr) Nouvelles préparation pharmaceutique pour administration orale.
IT8248908A0 (it) Composizione farmaceutica per la somministrazione per via orale dicomposti che debbono essere assorbiti nell'intestino crasso
GB2105193B (en) Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
IT8219947A0 (it) Complessi platino-diamminici eprocedimento per la loro preparazione nonche' formulazioni farmaceutiche antitumorali contenenti tali complessi.
DE3364234D1 (en) Antiphlogistic/antipyretic/analgesic pharmaceutical compositions containing theophylline derivatives as active ingredient
JPS56154417A (en) Use of 3,3'-azobis -(6-hydroxybenzoic acid) as drug and pharmaceutical composition containing it
FR2480603B1 (fr) Composition pharmaceutique pour administration par voie orale contenant de la cytidine-diphosphocholine
IT1151953B (it) Composizione farmaceutica per la cura di affezioni della cavita' orale
FR2580649B1 (fr) (-) - 1b - ethyl - 1a - hydroxymethyl -1,2,3,4,6,7,12,12ba-octahydroindolo(2,3-a) quinolizine, procede pour la preparer et compositions pharmaceutiques contenant celle-ci
FR2585953B1 (fr) Composition pharmaceutique pour l'administration orale contenant de l'ubiquinone et procede
BE887541A (fr) Medicament topique contenant de l'indomethacine
IT1118900B (it) Composizione farmaceutica contenente cefalosporina per somministrazione rettale
FR2609392B1 (fr) Compositions pharmaceutiques contenant des pyranoquinoleines
BE890011A (fr) Nouvelles compositions pharmaceutiques contenant de l'almitrine
IT1223132B (it) Composizione farmaceutica per somministrazione nasale
IT8221120A0 (it) Composizione farmaceutica per combattere l'aggregazione delle piastrine.
GB2105588B (en) Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
FR2530360B1 (fr) Regle pour la prescription de medicaments, notamment d'aminosides
BE892709A (fr) Nouvelles compositions pharmaceutiques topiques
FR2602680B1 (fr) Compositions pharmaceutiques pour l'administration par voie nasale

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: ITALFARMACO S.A.

Effective date: 19970331